Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kenneth C Anderson

Showing results (611-620 of 869) with videos related to

Pageof 87
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 24, 2006
Combination mammalian target of rapamycin inhibitor rapamycin and HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin has synergistic activity in multiple myelomaLanie K Francis, Yazan Alsayed, Xavier Leleu, et al.
Blood|May 4, 2007
Increased natural killer cell expression of CD16, augmented binding and ADCC activity to rituximab among individuals expressing the Fc{gamma}RIIIa-158 V/V and V/F polymorphismEvdoxia Hatjiharissi, Lian Xu, Daniel Ditzel Santos, et al.
Cancer Research|September 5, 2002
The vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584 inhibits growth and migration of multiple myeloma cells in the bone marrow microenvironmentBoris Lin, Klaus Podar, Deepak Gupta, et al.
Haematologica|June 30, 2011
Anti-tumor activity and signaling events triggered by the isothiocyanates, sulforaphane and phenethyl isothiocyanate, in multiple myelomaJana Jakubikova, David Cervi, Melissa Ooi, et al.
Blood|May 16, 2009
RhoA and Rac1 GTPases play major and differential roles in stromal cell-derived factor-1-induced cell adhesion and chemotaxis in multiple myelomaAbdel Kareem Azab, Feda Azab, Simona Blotta, et al.
Seminars in Hematology|May 12, 2023
Report of consensus Panel 4 from the 11th International Workshop on Waldenstrom's macroglobulinemia on diagnostic and response criteriaSteven P Treon, Alessandra Tedeschi, Jesus San-Miguel, et al.
Cancer Cell|April 10, 2007
The differentiation and stress response factor XBP-1 drives multiple myeloma pathogenesisDaniel R Carrasco, Kumar Sukhdeo, Marina Protopopova, et al.
American Journal of Hematology|January 22, 2024
Development and validation of an individualized and weighted Myeloma Prognostic Score System (MPSS) in patients with newly diagnosed multiple myelomaXuehan Mao, Wenqiang Yan, David Mery, et al.
Haematologica|August 23, 2023
Clinical perspectives on the optimal use of lenalidomide plus bortezomib and dexamethasone for the treatment of newly diagnosed multiple myelomaPaul G Richardson, Brian G Durie, Laura Rosiñol, et al.
British Journal of Haematology|June 3, 2015
Development of extramedullary myeloma in the era of novel agents: no evidence of increased risk with lenalidomide-bortezomib combinationsCindy Varga, Wanling Xie, Jacob Laubach, et al.
Pageof 87

Showing results (611-620 of 869) with videos related to

Sort By:
Pageof 87
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 24, 2006
Combination mammalian target of rapamycin inhibitor rapamycin and HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin has synergistic activity in multiple myelomaLanie K Francis, Yazan Alsayed, Xavier Leleu, et al.
Blood|May 4, 2007
Increased natural killer cell expression of CD16, augmented binding and ADCC activity to rituximab among individuals expressing the Fc{gamma}RIIIa-158 V/V and V/F polymorphismEvdoxia Hatjiharissi, Lian Xu, Daniel Ditzel Santos, et al.
Cancer Research|September 5, 2002
The vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584 inhibits growth and migration of multiple myeloma cells in the bone marrow microenvironmentBoris Lin, Klaus Podar, Deepak Gupta, et al.
Haematologica|June 30, 2011
Anti-tumor activity and signaling events triggered by the isothiocyanates, sulforaphane and phenethyl isothiocyanate, in multiple myelomaJana Jakubikova, David Cervi, Melissa Ooi, et al.
Blood|May 16, 2009
RhoA and Rac1 GTPases play major and differential roles in stromal cell-derived factor-1-induced cell adhesion and chemotaxis in multiple myelomaAbdel Kareem Azab, Feda Azab, Simona Blotta, et al.
Seminars in Hematology|May 12, 2023
Report of consensus Panel 4 from the 11th International Workshop on Waldenstrom's macroglobulinemia on diagnostic and response criteriaSteven P Treon, Alessandra Tedeschi, Jesus San-Miguel, et al.
Cancer Cell|April 10, 2007
The differentiation and stress response factor XBP-1 drives multiple myeloma pathogenesisDaniel R Carrasco, Kumar Sukhdeo, Marina Protopopova, et al.
American Journal of Hematology|January 22, 2024
Development and validation of an individualized and weighted Myeloma Prognostic Score System (MPSS) in patients with newly diagnosed multiple myelomaXuehan Mao, Wenqiang Yan, David Mery, et al.
Haematologica|August 23, 2023
Clinical perspectives on the optimal use of lenalidomide plus bortezomib and dexamethasone for the treatment of newly diagnosed multiple myelomaPaul G Richardson, Brian G Durie, Laura Rosiñol, et al.
British Journal of Haematology|June 3, 2015
Development of extramedullary myeloma in the era of novel agents: no evidence of increased risk with lenalidomide-bortezomib combinationsCindy Varga, Wanling Xie, Jacob Laubach, et al.
Pageof 87